Peg-interferon for hepatitis B with fatty liver
Part of Digestive system, Infections clinical trials.
This trial tests a medicine called peg-interferon for people who have both chronic hepatitis B and fatty liver. It aims to see if the treatment is safe and effective in helping your body fight the hepatitis B virus.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You must be between 18 and 60 years old.
- You have chronic hepatitis B (HBsAg positive for more than 6 months) and also have fatty liver diagnosed by imaging.
- Your hepatitis B virus level is undetectable (negative HBV DNA).
- You are not currently pregnant, breastfeeding, or planning to become pregnant during the study.
- You do not have cirrhosis, other active hepatitis infections (A, C, D, E, HIV), or serious mental health conditions like depression.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This study tests a lower dose of pegylated interferon for people with chronic hepatitis B whose virus levels dropped significantly during a previous interferon treatment. It aims to see if a second round can further reduce or clear the virus.
This trial tests a retreatment with pegylated interferon for people with chronic hepatitis B who have previously received interferon therapy and have seen their hepatitis B surface antigen (HBsAg) levels drop by at least half. The goal is to see if this retreatment can completely clear the virus from the blood.
This study looks at long-term outcomes in people with chronic hepatitis B who take antiviral medicines or receive interferon. It may help doctors understand which treatments work best over time and who is most likely to benefit.
This study tests a combination of two medicines for chronic hepatitis B: pegylated interferon and a nucleoside analogue. The goal is to see if this combo helps clear the hepatitis B surface antigen and improves the chance of a functional cure.
This study tests a new combination of antiviral medicine and an immune-boosting therapy for adults with chronic hepatitis B. It is designed for people who are in the active phase of the infection and have not been treated before.
This trial tests a new way to treat chronic hepatitis B in patients already taking antiviral medication. It combines a drug that helps the immune system fight the virus with another drug that boosts the immune response, aiming to improve chances of clearing the virus.
Hear when a new Non-Alcoholic Fatty Liver Disease trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.